Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. S. Luigi Hospital, Torino, Italy

Survival: 10.3 months
Toxicity Grade: 5
Treatments: Chemotherapy
Drugs: Pemetrexed
Country: Italy
City/State/Province: Torino
Hospital: S. Luigi Hospital
Journal: Link
Date: 7/2008

This study involved patients with advanced non-small cell lung cancer (NSCLC). Patients were divided into two separate treatment groups. Group A consisted of 862 patients with a median age of 61.1 years and 70% male. Group B had 863 patients with a median age of 61.0 years and 70.1% were male.

Group A was treated with the chemotherapy agents cisplatin and pemetrexed. Group B was treated with the chemotherapy agents cisplatin and gemcitabine.

Treatment-related deaths were reported for both treatment groups, 9 in group A and 6 in group B. Specific causes of death were not given. Other toxicities reported for group A included grade 3-4 neutropenia (15.1% of patients) and alopecia (11.9%). Patients in group B also reported grade 3-4 neutropenia (26.7%), alopecia (21.4%), and thrombocytopenia (12.7%).

The reported median overall survival for both group A and group B was 10.3 months.

This study was supported by Eli Lilly, the makers of pemetrexed and gemcitabine.

Correspondence: Dr. Giorgio Vittorio Scagliotti; email:

E-mail to a Friend Email Physician More Information